An investment thesis suggests IBRX could reprice significantly higher if a new administration, particularly one led by RFK Jr., prioritizes immune system-focused treatments over traditional cancer therapies, potentially overcoming current "big pharma" resistance. This is a speculative, long-term play contingent on political shifts and regulatory changes.